非TNFi生物和向合成DMARDs在类风湿关节炎相关的间歇性肺病:一个倾向性得分匹配的,活跃的比较器,新用户研究
Halie Frideres1, Christopher S Wichman1, Jianghu Dong1
1University of Nebraska Medical Center, Omaha, NE, USA.
Seminars in arthritis and rheumatism
|April 25, 2025
概括
在与类风湿性关节炎相关的间歇性肺病 (RA-ILD) 患者之间,没有发现死亡率或呼吸系统住院的显著差异,这些患者开始服用rituximab, abatacept,tocilizumab或tofacitinib. 对于RA-ILD中先进的免疫调节疗法,需要进行进一步的临床试验.
科学领域:
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 风湿性关节炎相关的间歇性肺病 (RA-ILD) 构成了重大的临床挑战.
- 非TNFi b/tsDMARDs越来越多地用于RA-ILD,但比较有效性数据有限.
研究的目的:
- 在RA-ILD患者中,比较Rituximab, abatacept,tocilizumab和tofacitinib的治疗结果.
- 模拟使用真实世界的数据来评估比较有效性的临床试验.
主要方法:
- 针对国家退伍军人事务数据 (2006-2020年) 应用的目标试验仿真框架.
- 在开始非TNFi b/tsDMARDs与rituximab的患者中,倾向性得分匹配 (1:1)
- 分析了三年来死亡和呼吸系统住院的综合结果.
主要成果:
- 治疗组之间没有观察到死亡率或呼吸系统住院的显著差异.
- 与rituximab相比,阿巴塔cept (aHR: 1.03),托西利祖马布 (aHR: 1.15) 和托法西提尼布 (aHR: 0.89) 没有显著的差异.
- 敏感性和子组分析支持了主要发现.
结论:
- 目前的非TNFi b/tsDMARDs在RA-ILD的死亡率和呼吸道住院治疗方面表现出类似的有效性.
- 不准确的估计和潜在的残留混需要谨慎解释.
- 临床试验对于最终评估RA-ILD的先进免疫调节疗法至关重要.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
Drugs Used in Lower Respiratory Disorders: Overview
244
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
244
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Antiasthma Drugs: Leukotriene Modifiers
150
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
150


